Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.76 |
| ▸ | PPARG | P37231 | 7/20 | 0.73 |
| ▸ | CTSS | P25774 | 3/20 | 0.58 |
| ▸ | CTSK | P43235 | 2/20 | 0.57 |
| ▸ | KLK7 | P49862 | 2/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.47 |
| ▸ | CDC25B | P30305 | 3/20 | 0.47 |
| ▸ | CDC25A | P30304 | 2/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5001071 | 1.00 | PPARA (0.76) | PPARAPPARGCTSSCTSKKLK7 | |
| SCHEMBL1374896 | 1.00 | PPARA (0.76) | PPARAPPARGCTSSCTSKKLK7 | |
| SCHEMBL12130757 | 0.94 | PPARA (0.85) | PPARAPPARGCTSSCTSKKLK7 | |
| SCHEMBL14058698 | 0.89 | PPARA (0.78) | PPARAPPARGCTSSCTSKKLK7 | |
| SCHEMBL14058699 | 0.89 | PPARA (0.78) | PPARAPPARGCTSSCTSKKLK7 | |
| SCHEMBL1132901 | 0.88 | PPARA (0.90) | PPARAPPARGCTSSCTSKKLK7 | |
| SCHEMBL17051 | 0.88 | PPARA (0.90) | PPARAPPARGCTSSCTSKKLK7 | |
| SCHEMBL828674 | 0.88 | PPARA (0.90) | PPARAPPARGCTSSCTSKKLK7 | |
| SCHEMBL5007500 | 0.88 | PPARA (0.73) | PPARAPPARGCTSSCTSKKLK7 | |
| SCHEMBL5007503 | 0.88 | PPARA (0.73) | PPARAPPARGCTSSCTSKKLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| WO-1992014706-A1 | CYCLOPENTANE-DERIVED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | PFIZER LIMITED (GB) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | PPARA 1880/4885PPARG 2471/4885CTSS 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.